$33.03
0.41.23%
At Close: -
$33.03
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
PTC Therapeutics
PTCTNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
PTC Therapeutics (NASDAQ:PTCT) Stock, Analyst Ratings, Price Targets, Forecasts
PTC Therapeutics Inc has a consensus price target of $37.94 based on the ratings of 18 analysts. The high is $62 issued by Cantor Fitzgerald on July 16, 2024. The low is $17 issued by Citigroup on October 27, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Morgan Stanley, and Cantor Fitzgerald on July 16, 2024, July 12, 2024, and July 1, 2024, respectively. With an average price target of $52 between Cantor Fitzgerald, Morgan Stanley, and Cantor Fitzgerald, there's an implied 57.43% upside for PTC Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
Morgan Stanley
B of A Securities
JP Morgan
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for PTC Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 87.71% | Cantor Fitzgerald | Kristen Kluska | $62 → $62 | Reiterates | Overweight → Overweight | Get Alert |
| 07/12/2024 | Buy Now | -3.12% | Morgan Stanley | Jeffrey Hung | $30 → $32 | Maintains | Equal-Weight | Get Alert |
| 07/01/2024 | Buy Now | 87.71% | Cantor Fitzgerald | Kristen Kluska | $52 → $62 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | -3.12% | B of A Securities | Tazeen Ahmad | $25 → $32 | Maintains | Underperform | Get Alert |
| 06/20/2024 | Buy Now | 60.46% | JP Morgan | Eric Joseph | $53 → $53 | Maintains | Overweight | Get Alert |
| 05/28/2024 | Buy Now | -3.12% | Goldman Sachs | Paul Choi | $18 → $32 | Maintains | Sell | Get Alert |
| 05/21/2024 | Buy Now | -21.28% | Citigroup | David Lebowitz | $18 → $26 | Maintains | Sell | Get Alert |
| 05/21/2024 | Buy Now | 60.46% | JP Morgan | Eric Joseph | $43 → $53 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -3.12% | Goldman Sachs | Paul Choi | $18 → $32 | Maintains | Sell | Get Alert |
| 05/20/2024 | Buy Now | 39.27% | Jefferies | Kelly Shi | $35 → $46 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | -9.17% | Morgan Stanley | Jeffrey Hung | $28 → $30 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 04/12/2024 | Buy Now | 36.24% | Cantor Fitzgerald | Kristen Kluska | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 5.96% | Jefferies | Kelly Shi | $33 → $35 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | -15.23% | RBC Capital | Brian Abrahams | → $28 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | -15.23% | RBC Capital | Brian Abrahams | $22 → $28 | Maintains | Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | 36.24% | Cantor Fitzgerald | Kristen Kluska | → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | -9.17% | TD Cowen | Joseph Thome | $32 → $30 | Maintains | Market Perform | Get Alert |
| 01/26/2024 | Buy Now | 36.24% | Cantor Fitzgerald | Kristen Kluska | $51 → $45 | Maintains | Overweight | Get Alert |
| 01/26/2024 | Buy Now | -33.39% | RBC Capital | Brian Abrahams | $27 → $22 | Maintains | Sector Perform | Get Alert |
| 12/19/2023 | Buy Now | -15.23% | Morgan Stanley | Jeffrey Hung | → $28 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 12/18/2023 | Buy Now | -45.5% | Goldman Sachs | Paul Choi | $20 → $18 | Maintains | Sell | Get Alert |
| 12/18/2023 | Buy Now | 54.41% | Cantor Fitzgerald | Kristen Kluska | → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 11/20/2023 | Buy Now | 54.41% | Cantor Fitzgerald | Kristen Kluska | → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 10/27/2023 | Buy Now | -15.23% | Morgan Stanley | Jeffrey Hung | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -24.31% | Barclays | Gena Wang | $26 → $25 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -48.53% | Citigroup | David Lebovitz | $29 → $17 | Downgrade | Neutral → Sell | Get Alert |
| 10/06/2023 | Buy Now | -24.31% | Truist Securities | Robyn Karnauskas | → $25 | Downgrade | Buy → Hold | Get Alert |
| 09/19/2023 | Buy Now | 36.24% | Truist Securities | Barry Jonas | → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | -30.37% | B of A Securities | Tazeen Ahmad | $43 → $23 | Maintains | Underperform | Get Alert |
| 09/18/2023 | Buy Now | 36.24% | Truist Securities | Barry Jonas | $60 → $45 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | -21.28% | Barclays | Gena Wang | $44 → $26 | Maintains | Equal-Weight | Get Alert |
| 09/18/2023 | Buy Now | -6.15% | Morgan Stanley | Jeffrey Hung | $47 → $31 | Maintains | Equal-Weight | Get Alert |
| 09/18/2023 | Buy Now | -33.39% | Goldman Sachs | Paul Choi | $35 → $22 | Maintains | Sell | Get Alert |
| 09/18/2023 | Buy Now | -21.28% | RBC Capital | Brian Abrahams | $49 → $26 | Maintains | Sector Perform | Get Alert |
| 09/18/2023 | Buy Now | -12.2% | Citigroup | David Lebovitz | $55 → $29 | Downgrade | Buy → Neutral | Get Alert |
| 09/18/2023 | Buy Now | — | Raymond James | Danielle Brill | — | Downgrade | Outperform → Underperform | Get Alert |
| 09/15/2023 | Buy Now | — | Raymond James | Danielle Brill | — | Downgrade | Outperform → Underperform | Get Alert |
| 08/16/2023 | Buy Now | 96.79% | Truist Securities | Barry Jonas | → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 121.01% | Cantor Fitzgerald | Kristen Kluska | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 42.29% | Morgan Stanley | Jeffrey Hung | $47 → $47 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 33.21% | Barclays | Gena Wang | $48 → $44 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 66.52% | Raymond James | Danielle Brill | $58 → $55 | Maintains | Outperform | Get Alert |
| 07/21/2023 | Buy Now | 121.01% | Cantor Fitzgerald | Kristen Kluska | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 07/20/2023 | Buy Now | 48.35% | RBC Capital | Brian Abrahams | → $49 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/20/2023 | Buy Now | 121.01% | Cantor Fitzgerald | Kristen Kluska | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 07/20/2023 | Buy Now | 51.38% | Credit Suisse | Judah Frommer | → $50 | Reiterates | Neutral → Neutral | Get Alert |
| 07/11/2023 | Buy Now | 42.29% | Morgan Stanley | Jeffrey Hung | $50 → $47 | Maintains | Equal-Weight | Get Alert |
| 06/30/2023 | Buy Now | 121.01% | Cantor Fitzgerald | Kristen Kluska | $75 → $73 | Maintains | Overweight | Get Alert |
| 05/24/2023 | Buy Now | 27.16% | B of A Securities | Tazeen Ahmad | → $42 | Maintains | Underperform | Get Alert |
| 05/24/2023 | Buy Now | 57.43% | RBC Capital | Brian Abrahams | → $52 | Maintains | Sector Perform | Get Alert |
| 05/24/2023 | Buy Now | 51.38% | Credit Suisse | Judah Frommer | $55 → $50 | Maintains | Neutral | Get Alert |
| 05/24/2023 | Buy Now | 21.1% | TD Cowen | Joseph Thome | $47 → $40 | Maintains | Market Perform | Get Alert |
| 05/24/2023 | Buy Now | 90.74% | Citigroup | David Lebovitz | $70 → $63 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 45.32% | Barclays | Gena Wang | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | 30.18% | B of A Securities | Tazeen Ahmad | $36 → $43 | Maintains | Underperform | Get Alert |
| 05/18/2023 | Buy Now | 111.93% | Citigroup | David Lebovitz | $67 → $70 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | 72.57% | Barclays | Gena Wang | $47 → $57 | Maintains | Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | 12.02% | Goldman Sachs | Paul Choi | $35 → $37 | Maintains | Sell | Get Alert |
| 05/08/2023 | Buy Now | 93.76% | JP Morgan | Eric Joseph | $57 → $64 | Maintains | Overweight | Get Alert |
| 05/01/2023 | Buy Now | 75.6% | Raymond James | Danielle Brill | $55 → $58 | Maintains | Outperform | Get Alert |
| 04/28/2023 | Buy Now | 54.41% | Credit Suisse | Judah Frommer | $48 → $51 | Maintains | Neutral | Get Alert |
| 04/28/2023 | Buy Now | 102.85% | Citigroup | David Lebovitz | $61 → $67 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 96.79% | Truist Securities | Barry Jonas | $60 → $65 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 45.32% | SVB Leerink | Joseph Schwartz | → $48 | Initiates | → Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 66.52% | Raymond James | Danielle Brill | $60 → $55 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | 8.99% | B of A Securities | Tazeen Ahmad | → $36 | Maintains | Underperform | Get Alert |
| 02/22/2023 | Buy Now | 99.82% | Cantor Fitzgerald | Kristen Kluska | $68 → $66 | Maintains | Overweight | Get Alert |
| 02/22/2023 | Buy Now | 45.32% | Credit Suisse | Judah Frommer | → $48 | Reiterates | → Neutral | Get Alert |
| 02/03/2023 | Buy Now | 51.38% | Morgan Stanley | Jeffrey Hung | $40 → $50 | Maintains | Equal-Weight | Get Alert |
| 01/10/2023 | Buy Now | 45.32% | Credit Suisse | Judah Frommer | $47 → $48 | Maintains | Neutral | Get Alert |
| 12/14/2022 | Buy Now | 5.96% | Goldman Sachs | Paul Choi | → $35 | Initiates | → Sell | Get Alert |
| 10/28/2022 | Buy Now | 42.29% | Barclays | Gena Wang | $48 → $47 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 21.1% | Morgan Stanley | Jonathan Lee | $54 → $40 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 39.27% | RBC Capital | Brian Abrahams | $60 → $46 | Maintains | Sector Perform | Get Alert |
| 10/28/2022 | Buy Now | 42.29% | Credit Suisse | Judah Frommer | $55 → $47 | Maintains | Neutral | Get Alert |
| 10/17/2022 | Buy Now | 81.65% | RBC Capital | Brian Abrahams | $49 → $60 | Maintains | Sector Perform | Get Alert |
| 09/12/2022 | Buy Now | 87.71% | Jefferies | Kelly Shi | → $62 | Initiates | → Buy | Get Alert |
| 09/09/2022 | Buy Now | 63.49% | Morgan Stanley | Andrew Galler | → $54 | Initiates | → Equal-Weight | Get Alert |
| 09/01/2022 | Buy Now | 111.93% | Citigroup | David Lebowitz | → $70 | Initiates | → Buy | Get Alert |
| 08/11/2022 | Buy Now | 81.65% | Raymond James | Danielle Brill | $55 → $60 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 45.32% | Barclays | Gena Wang | → $48 | Maintains | Equal-Weight | Get Alert |
| 06/23/2022 | Buy Now | 39.27% | RBC Capital | Brian Abrahams | $42 → $46 | Maintains | Sector Perform | Get Alert |
| 05/04/2022 | Buy Now | 2.94% | Barclays | Gena Wang | $39 → $34 | Maintains | Equal-Weight | Get Alert |
| 04/19/2022 | Buy Now | -0.09% | B of A Securities | Tazeen Ahmad | $34 → $33 | Maintains | Underperform | Get Alert |
| 02/23/2022 | Buy Now | 130.09% | JP Morgan | Eric Joseph | $70 → $76 | Maintains | Overweight | Get Alert |
| 02/23/2022 | Buy Now | 18.07% | Barclays | Gena Wang | $40 → $39 | Maintains | Equal-Weight | Get Alert |
| 10/29/2021 | Buy Now | 21.1% | Barclays | Gena Wang | $45 → $40 | Maintains | Equal-Weight | Get Alert |
| 10/29/2021 | Buy Now | 66.52% | Raymond James | Danielle Brill | — | Maintains | Outperform | Get Alert |
| 10/29/2021 | Buy Now | 27.16% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 10/29/2021 | Buy Now | 45.32% | Credit Suisse | Judah Frommer | — | Maintains | Neutral | Get Alert |
| 10/18/2021 | Buy Now | 15.05% | B of A Securities | Tazeen Ahmad | — | Downgrade | Neutral → Underperform | Get Alert |
| 07/30/2021 | Buy Now | 51.38% | Credit Suisse | Judah Frommer | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for PTC Therapeutics (PTCT) stock?
The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by Cantor Fitzgerald on July 16, 2024. The analyst firm set a price target for $62.00 expecting PTCT to rise to within 12 months (a possible 87.71% upside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PTC Therapeutics (PTCT)?
The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by Cantor Fitzgerald, and PTC Therapeutics reiterated their overweight rating.
When was the last upgrade for PTC Therapeutics (PTCT)?
The last upgrade for PTC Therapeutics Inc happened on April 29, 2024 when Morgan Stanley raised their price target to $30. Morgan Stanley previously had an underweight for PTC Therapeutics Inc.
When was the last downgrade for PTC Therapeutics (PTCT)?
The last downgrade for PTC Therapeutics Inc happened on December 19, 2023 when Morgan Stanley changed their price target from N/A to $28 for PTC Therapeutics Inc.
When is the next analyst rating going to be posted or updated for PTC Therapeutics (PTCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating PTC Therapeutics (PTCT) correct?
While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a reiterated with a price target of $62.00 to $62.00. The current price PTC Therapeutics (PTCT) is trading at is $33.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.